Evidence map›Paper›PMID 34882906›Full record

ReviewCell biology international2022

The role of mesenchymal stem cells in liver injury.

Haoyu Sun, Chuanyin Shi, Zhenlong Ye, Bi Yao, Chen Li, Xiaobing Wang, Qijun Qian

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell biology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. The role of mesenchymal stem cells in liver injury.Cell biology international · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Haoyu SunShanghai Cell Therapy Group, Shanghai, China.
Chuanyin ShiShanghai Cell Therapy Group, Shanghai, China.
Zhenlong YeShanghai Cell Therapy Group, Shanghai, China.
Bi YaoShanghai Cell Therapy Group, Shanghai, China.
Chen LiShanghai Cell Therapy Group, Shanghai, China.
Xiaobing WangShanghai Cell Therapy Group, Shanghai, China.
Qijun QianShanghai Cell Therapy Group, Shanghai, China.ORCID http://orcid.org/0000-0002-3285-5009

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, mesenchymal stem cell (MSC) therapy has been suggested as an effective alternative approach for the treatment of hepatic diseases. MSCs have potential therapeutic value, because they have high self-renewal ability, are capable of multipotent differentiation, and have low immunogenicity. Furthermore, MSCs have the potential to differentiate into hepatocytes, and the therapeutic value exists in their immune-modulatory properties and secretion of trophic factors, such as growth factors and cytokines. Moreover, MSCs can suppress inflammatory responses, reduce hepatocyte apoptosis, increase hepatocyte regeneration, regress liver fibrosis, and enhance liver functionality.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationCell DifferentiationHepatocytesHumansLiverLiver Cirrhosisimmunomodulatoryliver fibrosisliver injurymesenchymal stem cell

Identifiers

PMID34882906
PMCPMC9303694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.